2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 295-296
Technology and Procedures, Omics Technologies, Bioinformatics, Treatment Considerations, Biological Therapies, Transplantation, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Metabolism, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult
PAPER

611 Hematopoietic cell transplantation without radiation or DNA alkylating agents in bone marrow failure with short telomeres

Suneet Agarwal, MD PHD, Kasiani C. Myers I, MD2, Paibel Aguayo-Hiraldo, MD3, Joseph Antin, MD4, Alison A. Bertuch, MD, PhD5, Farid Boulad, MD6, Jochen Buechner, MD PHD7, Lauri Burroughs, MD8, Yi-Bin Chen, MD,MS9, Corey Cutler, MD,FRCPC,MPH10, Alfred P Gillio, MD11, Aric Hall, MD12, Erin Hall, MD13, Inga Hofmann, MD PHD14, William Hogan, M.B., B.Ch.15, Mark B. Juckett, MD, MHCM16, James LaBelle, MD, PhD17, Paul Martin, MD PHD18, Timothy S. Olson, MD, PhD19, Mrinal M. Patnaik, MD, MBBS20, Vinod Prasad, MD, MBBS21, Michael A. Pulsipher, MD22, Ghadir Sasa, MD23, Mikael Sundin, MD PHD24, Pei-Chi Kao, PHD25, Wendy London, PhD26, David A. Williams, MD27, Leslie Lehmann, MD28
1 Boston Children's Hospital, Boston, Massachusetts, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Children's Hospital Los Angeles, Los Angeles, California, United States, University of Southern California, Los Angeles, California, United States
4 Dana Farber Cancer Institute, Boston, Massachusetts, United States
5 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Oslo University Hospital, Oslo, Norway
8 Fred Hutch Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
9 Massachusetts General Hospital, Boston, Massachusetts, United States
10 Dana Farber Cancer Institute, Boston, Massachusetts, United States
11 Hackensack University Medical Center, Hackensack, New Jersey, United States, Joseph M. Sanzari Children's Hospital, Hackensack, United States
12 University of Wisconsin-Madison, Madison, Wisconsin, United States
13 Children's Mercy, Kansas City, Missouri, United States
14 University of Wisconsin-Madison, Madison, Wisconsin, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 University of Wisconsin-Madison, Madison, Wisconsin, United States
17 Comer Children's Hospital, Chicago, Illinois, United States, UChicago Medicine, Chicago, Illinois, United States
18 Duke University, Durham, North Carolina, United States
19 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Duke University, Durham, North Carolina, United States
22 Children's Hospital Los Angeles, Los Angeles, California, United States
23 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
24 Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden
25 Boston Children's Hospital, Boston, Massachusetts, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States
26 Boston Children's Hospital, Boston, Massachusetts, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
27 Boston Children's Hospital, Boston, Massachusetts, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
28 Boston Children's Hospital, Boston, Massachusetts, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Background: Radiation and/or DNA alkylating agents are universally employed to achieve myeloid engraftment in hematopoietic cell transplantation (HCT), but their non-specific genotoxicity contributes to organ damage, secondary malignancy, and death. These risks are heightened in patients with certain genetic bone marrow failure (BMF) syndromes including dyskeratosis congenita (DC), which arises from defects in telomere maintenance. In historical cohorts, treatment-related mortality (TRM) occurred in 20–30% of DC patients within 6 months of HCT, with worse outcomes in mismatched donor transplants and those with comorbidities, curtailing the use of HCT in this patient population. We hypothesized that the proliferative defects in hematopoietic cells of patients with BMF and very short telomeres might permit the successful engraftment of normal donor stem cells without the need for radiation or DNA alkylating agents, and this would be associated with improved outcomes. We conducted the first international multi-center prospective trial evaluating myeloid engraftment and outcomes after HCT without these agents (NCT01659606).

Methods: We enrolled children and adults with BMF and a genetic diagnosis of DC / telomere biology disorder (TBD) or lymphocyte telomere length <1st percentile as measured by flow cytometry-based fluorescence in situ hybridization. HCT, preceded by a preparative regimen consisting of only alemtuzumab (0.2 mg/kg x 5 days) and fludarabine (30 mg/m2 x 6 days), was performed using bone marrow allografts from related or unrelated donors matched at 7 or 8 of 8 HLA alleles. Graft versus host disease (GVHD) prophylaxis consisted of a calcineurin inhibitor and mycophenolate mofetil. The primary endpoint was donor myeloid engraftment, defined as an absolute neutrophil count (ANC) ≥500 cells/µL by day +42 and donor myeloid chimerism >50% by day +100.

Results: Forty patients ages 1.7–51 years (13 were ≥18 years old) enrolled and received allogeneic HCT between August 2012 and January 2023 at 15 institutions. Thirty-four of the 40 patients (85%) received unrelated donor grafts (20 matched, 14 mismatched). Primary myeloid engraftment was achieved in 39 of 40 patients at a median of 22 days post-HCT (range 2–41 days), yielding a 42-day cumulative incidence of 97.5% (95% CI: 73–99.8%). The single patient with primary graft failure had DC-related liver disease and hypersplenism; in this case, splenectomy at day +47 resulted in immediate ANC recovery, revealing that she had achieved donor myeloid engraftment. Of the other 39 patients, 31 had sustained myeloid engraftment. Eight patients developed secondary graft failure. One of these patients maintained high donor chimerism after primary engraftment but developed severe neutropenia in the setting of multiple viral reactivations and died of a fungal infection 91 days post-HCT. The other 7 patients had allograft rejection, all within 105 days of transplant; 6 underwent successful repeat HCT using higher-intensity regimens, and 1 had autologous reconstitution without repeat HCT. Two of the 31 patients with durable engraftment under the protocol regimen had grade II-IV acute GVHD, which resolved after systemic corticosteroids. Eight of the 31 had chronic GVHD (4 limited, 4 extensive), with documented resolution in 6 patients. Infectious complications included cytomegalovirus (16/40; 40%), Epstein-Barr virus (11/40; 28%), and adenovirus (1/40; 3%). The 100-day, 2-year, and 5-year overall survival rates (95% CI) were 95% (81–99%), 90% (76–96%), and 82% (66–91%), respectively. Twelve patients died: 3 due to TRM (7.5%), all within 200 days of HCT and all from infectious causes; the other 9 patients died between 1.6 and 13.8 years post-HCT, 8 from non-hematologic causes related to their underlying disease and 1 from unknown causes. The median follow-up was 5.1 years (range 3.0–11.0 years) for the 28 patients alive at last contact.

Conclusions: This radiation- and alkylator-free HCT conditioning regimen is an effective strategy for BMF in patients with DC/TBD or very short lymphocyte telomeres. Eliminating DNA damaging agents may reduce HCT complications including GVHD and enable transplant in patients with high-risk comorbidities. This approach may be applicable in other BMF disorders characterized by hematopoietic stem cell failure. This is the first series of patients in allogeneic HCT to achieve durable myeloid engraftment without any exposure to alkylating agents or radiation.

Suneet Agarwal, MD PHD: Cimeio Therapeutics - Current holder of stock options in a privately-held company